Jazz Pharmaceuticals JAZZ Net debt / EBITDA

Net debt / EBITDA at other companies

AmgenAMGN

3.5×-0.5×

AlkermesALKS

5.9×+5.1×

Stoke Therapeutics, Inc.STOK

-2.8×—

Harmony Biosciences Holdings, Inc.HRMY

-2×+1.3×

XER

Xeris Biopharma Holdings, Inc.XERS

4.4×—

Zevra Therapeutics, Inc.ZVRA

-1.6×—

FAQ

What is Jazz Pharmaceuticals's net debt / EBITDA?

Jazz Pharmaceuticals (JAZZ) reported net debt / EBITDA of 5.6× in Q1 2025.

How has Jazz Pharmaceuticals's net debt / EBITDA changed year-over-year?

Jazz Pharmaceuticals's net debt / EBITDA decreased by 28.4% year-over-year, from 7.9× to 5.6×.

What is the long-term trend for Jazz Pharmaceuticals's net debt / EBITDA?

Over 3 years (2020 to 2024), Jazz Pharmaceuticals's net debt / EBITDA has grown at a 18.6% compound annual growth rate (CAGR), from 3× to 5×.

What does net debt / EBITDA mean?

Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.